Inge M.W. Verberk

4.5k total citations · 3 hit papers
74 papers, 2.2k citations indexed

About

Inge M.W. Verberk is a scholar working on Physiology, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, Inge M.W. Verberk has authored 74 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Physiology, 47 papers in Psychiatry and Mental health and 17 papers in Molecular Biology. Recurrent topics in Inge M.W. Verberk's work include Alzheimer's disease research and treatments (53 papers), Dementia and Cognitive Impairment Research (45 papers) and Statistical Methods in Clinical Trials (8 papers). Inge M.W. Verberk is often cited by papers focused on Alzheimer's disease research and treatments (53 papers), Dementia and Cognitive Impairment Research (45 papers) and Statistical Methods in Clinical Trials (8 papers). Inge M.W. Verberk collaborates with scholars based in Netherlands, United States and Sweden. Inge M.W. Verberk's co-authors include Charlotte E. Teunissen, Wiesje M. van der Flier, Philip Scheltens, Erik Stoops, Kaj Blennow, Henrik Zetterberg, Niels D. Prins, Sander C.J. Verfaillie, Bart N.M. van Berckel and Hugo Vanderstichele and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Annals of Neurology.

In The Last Decade

Inge M.W. Verberk

66 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease

2021 276 citations Pratishtha Chatterjee, Steve Pedrini et al. Translational Psychiatry profile →
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

2021 267 citations Charlotte E. Teunissen, Henrik Zetterberg et al. profile →
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease

2024 34 citations Michael Schöll, Inge M.W. Verberk et al. The Lancet Healthy Longevity profile →

Peers

Inge M.W. Verberk

PHYSI

PMH

NEURO

Juan Lantero‐Rodriguez Sweden

Christoffer Rosén Sweden

Nathalie Le Bastard Belgium

Niki S.M. Schoonenboom Netherlands

Nicolas R. Barthélemy United States

Tobias Skillbäck Sweden

Maartje I. Kester Netherlands

Małgorzata Knapik-Czajka Poland

Henrik Zetterberg Sweden

Janna H. Neltner United States

Juan Lantero‐Rodriguez Sweden

Inge M.W. Verberk

1.8k ×1.2

PHYSI

1.4k ×1.2

PMH

424 ×0.9

NEURO

733 ×1.5

350 ×0.9

NEURO

Citations per year, relative to Inge M.W. Verberk Inge M.W. Verberk (= 1×) peers Juan Lantero‐Rodriguez

Countries citing papers authored by Inge M.W. Verberk

Since Specialization

Citations

This map shows the geographic impact of Inge M.W. Verberk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge M.W. Verberk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge M.W. Verberk more than expected).

Fields of papers citing papers by Inge M.W. Verberk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge M.W. Verberk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge M.W. Verberk. The network helps show where Inge M.W. Verberk may publish in the future.

Co-authorship network of co-authors of Inge M.W. Verberk

This figure shows the co-authorship network connecting the top 25 collaborators of Inge M.W. Verberk. A scholar is included among the top collaborators of Inge M.W. Verberk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge M.W. Verberk. Inge M.W. Verberk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trieu, Calvin, Argonde C. van Harten, Sietske A.M. Sikkes, et al.. (2025). Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline. JAMA Network Open. 8(12). e2545862–e2545862.

Wilson, David H., Gallen Triana‐Baltzer, Karen Copeland, et al.. (2025). Analytical and clinical validation of a high accuracy fully automated digital immunoassay for plasma phospho-Tau 217 for clinical use in detecting amyloid pathology. SHILAP Revista de lepidopterología. 16. 1568971–1568971. 2 indexed citations

Verberk, Inge M.W., et al.. (2024). The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases. Journal of Neurochemistry. 169(1). e16226–e16226. 10 indexed citations

Groot, Colin, H. Stevie Tan, Jurre den Haan, et al.. (2024). Rationale and design of the BeyeOMARKER study: prospective evaluation of blood- and eye-based biomarkers for early detection of Alzheimer’s disease pathology in the eye clinic. Alzheimer s Research & Therapy. 16(1). 190–190. 4 indexed citations

Bouteloup, Vincent, Wiesje M. van der Flier, Charlotte E. Teunissen, et al.. (2024). Development and assessment of algorithms for predicting brain amyloid positivity in a population without dementia. Alzheimer s Research & Therapy. 16(1). 219–219. 1 indexed citations

Alam, John, et al.. (2024). Neflamapimod treatment reduces plasma glial fibriallary acidic protein levels in patients with pure dementia with Lewy bodies (DLB). Alzheimer s & Dementia. 20(S6).

Gerritsen, Lotte, Inge M.W. Verberk, Charlotte E. Teunissen, et al.. (2024). Plasma Markers of Alzheimer's Disease Pathology, Neuronal Injury, and Astrocytic Activation and MRI Load of Vascular Pathology and Neurodegeneration: The SMART‐MR Study. Journal of the American Heart Association. 13(4). e032134–e032134. 6 indexed citations

Schöll, Michael, Inge M.W. Verberk, Marta del Campo, et al.. (2024). Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease. The Lancet Healthy Longevity. 5(10). 100630–100630. 34 indexed citations breakdown →

Harten, Argonde C. van, Afina W. Lemstra, Yolande A.L. Pijnenburg, et al.. (2024). Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 16(4). e70003–e70003. 6 indexed citations

10.

Wilson, David H., Karen Copeland, Lyndal K. Hesterberg, et al.. (2024). Multi‐Marker Approach to Reducing the Intermediate Range of a High Accuracy 2‐Cutoff Plasma p‐Tau 217 Test for Amyloid Detection. Alzheimer s & Dementia. 20(S8). 2 indexed citations

11.

Vanbrabant, Jeroen, Sjors G. J. G. In ‘t Veld, Rebecca M. Edelmayer, et al.. (2023). Plasma phosphorylated tau 217 levels are highly stable under common pre‐analytical sample handling procedures. Alzheimer s & Dementia. 19(S14). 1 indexed citations

12.

Verberk, Inge M.W., Anouk den Braber, David Wilson, et al.. (2023). A prospective study investigating the relation between blood‐based biomarkers for Alzheimer’s disease and diagnosis/patient management in primary care: The CANTATE‐PC study. Alzheimer s & Dementia. 19(S14).

13.

Hendriksen, Heleen M.A., John Harrison, Everard G.B. Vijverberg, et al.. (2023). Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups. Neurology. 102(2). e207978–e207978. 18 indexed citations

14.

Roberts, Blaine R., Inge M.W. Verberk, Kevin E. Yarasheski, et al.. (2023). Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 15(4). e12496–e12496. 2 indexed citations

15.

Vanbrabant, Jeroen, Sherif Bayoumy, Inge M.W. Verberk, et al.. (2023). Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217. Alzheimer s & Dementia. 19(S24). 2 indexed citations

16.

Gerritsen, Lotte, Inge M.W. Verberk, Charlotte E. Teunissen, et al.. (2022). Association between plasma Alzheimer’s disease markers and MRI markers of cerebral small vessel disease and neurodegeneration: the SMART‐MR Study. Alzheimer s & Dementia. 18(S6). 1 indexed citations

17.

Verberk, Inge M.W., et al.. (2021). Pre-Analytical Sample Handling Effects on Blood Cytokine Levels: Quality Control of A Covid-19 Biobank. Biomarkers in Medicine. 15(12). 987–997. 9 indexed citations

18.

Verberk, Inge M.W., Karlijn A. van den Bosch, Jarith L. Ebenau, et al.. (2021). Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. The Lancet Healthy Longevity. 2(2). e87–e95. 129 indexed citations

19.

Chatterjee, Pratishtha, Steve Pedrini, Erik Stoops, et al.. (2021). Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Translational Psychiatry. 11(1). 27–27. 276 indexed citations breakdown →

20.

Thijssen, Elisabeth H., Inge M.W. Verberk, Jeroen Vanbrabant, et al.. (2021). Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease. Scientific Reports. 11(1). 9736–9736. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact